NCT00447577

Zylet vs TobraDex in Blepharokeratoconjunctivitis

A Clinical Safety and Efficacy Evaluation of Zylet (Loteprednol Etabonate and Tobramycin Ophthalmic Suspension) vs. Tobradex (Tobramycin and Dexamethasone Ophthalmic Suspension) in the Treatment of Blepharokeratoconjunctivitis

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 276 (actual)
• Sponsor: Bausch & Lomb Incorporated · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to evaluate the safety and efficacy of Zylet vs. Tobradex in the treatment of ocular inflammation associated with blepharokeratoconjunctivitis

Conditions

• Blepharokeratoconjunctivitis

Interventions

Type	Name	Description
DRUG	Loteprednol etabonate and tobramycin ophthalmic suspension	Subjects will self-administer the study drug in the affected eye(s) 4 times a day (QID) for 14 days.
DRUG	Tobramycin and dexamethasone ophthalmic suspension	Subjects will self-administer the study drug in the affected eye(s) 4 times a day (QID) for 14 days.

Timeline

• Start date: 2007-01-01
• Primary completion: 2007-06-01
• Completion: 2007-06-01
• First posted: 2007-03-14
• Last updated: 2011-12-09

Locations

1 site across 1 country: United States